Medulloblastomas: Update on a heterogeneous disease

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 630-637

  Bourdeaut, Franck ^a   Miquel, Catherine ^b,c   Alapetite, Claire ^d   Roujeau, Thomas ^d   Doz, Francois ^a  

^a INSTITUT CURIE   (France)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

biological markers; long term sequelae; medulloblastoma; risk stratification

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; LOMUSTINE; METHOTREXATE; SONIC HEDGEHOG PROTEIN; VINCRISTINE; WNT PROTEIN;

ANASTOMOSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHILDHOOD CANCER; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LONG TERM CARE; MEDULLOBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTON THERAPY; RADIATION DOSE; REVIEW;

ADOLESCENT; ANIMALS; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; HUMANS; MEDULLOBLASTOMA;

EID: 80054102410     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834ace3f     Document Type: Review

References (85)

1. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995; 332:839-847.
2. Levanat S, Gorlin RJ, Fallet S, et al. A two-hit model for developmental defects in Gorlin syndrome. Nat Genet 1996; 12:85-87. (Pubitemid 26011325)
3. Distel L, Neubauer S, Varon R, et al. Fatal toxicity following radio-and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. Med Pediatr Oncol 2003; 41:44-48. (Pubitemid 41103253)
4. Skousen GJ, Wardinsky T, Chenaille P. Medulloblastoma in patient with Rubinstein-Taybi syndrome. Am J Med Genet 1996; 66:367.
5. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002; 31:306-310.
6. Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 2010; 121:381-396.
7. Von Hoff K, Hartmann W, von Bueren AO, et al. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors. Pediatr Blood Cancer 2010; 54:369-376.
8. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): longterm results from a prospective, multicentre trial. Lancet Oncol 2006; 7:813-820. (Pubitemid 44464063)
9. Giangaspero F, Rigobello L, Badiali M, et al. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol 1992; 16:687-693.
10. Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol 2010; 28:4961-4968.
11. Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29:1424-1430.
12. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008; 3:e3088.
13. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29:1408-1414.
14. Evans DG, Farndon PA, Burnell LD, et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991; 64:959-961.
15. Garre ML, Cama A, Bagnasco F, et al. Medulloblastoma variants: agedependent occurrence and relation to Gorlin syndrome-a new clinical perspective. Clin Cancer Res 2009; 15:2463-2471.
16. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277:1109-1113. (Pubitemid 27371635)
17. Ayrault O, Zhao H, Zindy F, et al. Atoh1 inhibits neuronal differentiation and collaborates with Gli1 to generate medulloblastoma- initiating cells. Cancer Res 2010; 70:5618-5627.
18. Ellison DW, Onilude OE, Lindsey JC, et al. Beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005; 23:7951-7957. (Pubitemid 46657395)
19. Fattet S, Haberler C, Legoix P, et al. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 2009; 218:86-94.
20. Clifford SC, Lusher ME, Lindsey JC, et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006; 5:2666-2670.
21. Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010; 468:1095-1099.
22. Brasme JF, Chalumeau M, Doz F, et al. Interval between onset of symptoms and diagnosis of medulloblastoma in children: distribution and determinants in a population-based study. Eur J Pediatr 2011. [Epub ahead of print]
23. Wilne S, Collier J, Kennedy C, et al. Presentation of childhood CNS tumours: a systematic review and meta-analysis. Lancet Oncol 2007; 8:685-695. (Pubitemid 47163575)
24. Jaremko JL, Jans LB, Coleman LT, Ditchfield MR. Value and limitations of diffusion-weighted imaging in grading and diagnosis of pediatric posterior fossa tumors. AJNR Am J Neuroradiol 2010; 31:1613-1616.
25. Fritsch MJ, Doerner L, Kienke S, Mehdorn HM. Hydrocephalus in children with posterior fossa tumors: role of endoscopic third ventriculostomy. J Neurosurg 2005; 103:40-42. (Pubitemid 44954946)
26. Debeneix C, Bourgeois M, Trivin C, et al. Hypothalamic hamartoma: comparison of clinical presentation and magnetic resonance images. Horm Res 2001; 56:12-18. (Pubitemid 34124181)
27. Sainte-Rose C, Cinalli G, Roux FE, et al. Management of hydrocephalus in pediatric patients with posterior fossa tumors: the role of endoscopic third ventriculostomy. J Neurosurg 2001; 95:791-797. (Pubitemid 33043352)
28. Santos de Oliveira R, Barros Juca CE, Valera ET, Machado HR. Hydrocephalus in posterior fossa tumors in children. Are there factors that determine a need for permanent cerebrospinal fluid diversion? Childs Nerv Syst 2008; 24:1397-1403.
29. Bhatia R, Tahir M, Chandler CL. The management of hydrocephalus in children with posterior fossa tumours: the role of preresectional endoscopic third ventriculostomy. Pediatr Neurosurg 2009; 45:186-191.
30. Turgut M. Cerebellar mutism. J Neurosurg Pediatr 2008; 1:262. (Pubitemid 351346520)
31. Gudrunardottir T, Sehested A, Juhler M, Schmiegelow K. Cerebellar mutism: incidence, risk factors and prognosis. Childs Nerv Syst 2011; 27:513-514; author reply 515.
32. Dietze DD Jr, Mickle JP. Cerebellar mutism after posterior fossa surgery. Pediatr Neurosurg 1990; 16:25-31; discussion 31.
33. Kellogg JX, Piatt JH Jr. Resection of fourth ventricle tumors without splitting the vermis: the cerebellomedullary fissure approach. Pediatr Neurosurg 1997; 27:28-33. (Pubitemid 28067183)
34. Kusano Y, Tanaka Y, Takasuna H, et al. Transient cerebellar mutism caused by bilateral damage to the dentate nuclei after the second posterior fossa surgery. Case report. J Neurosurg 2006; 104:329-331.
35. Grill J, Viguier D, Kieffer V, et al. Critical risk factors for intellectual impairment in children with posterior fossa tumors: the role of cerebellar damage. J Neurosurg 2004; 101:152-158. (Pubitemid 39426188)
36. Zaheer SN, Wood M. Experiences with the telovelar approach to fourth ventricular tumors in children. Pediatr Neurosurg 2010; 46:340-343.
37. Cheng WY, Chao SC, Shen CC. Endoscopic microvascular decompression of the hemifacial spasm. Surg Neurol 2008; 70 (Suppl 1):40-46.
38. Gangemi M, Maiuri F, Colella G, Sardo L. Endoscopic surgery for large posterior fossa arachnoid cysts. Minim Invasive Neurosurg 2001; 44:21-24. (Pubitemid 32435769)
39. Jarrahy R, Berci G, Shahinian HK. Endoscope-assisted microvascular decompression of the trigeminal nerve. Otolaryngol Head Neck Surg 2000; 123:218-223.
40. Grill J, Lellouch-Tubiana A, Elouahdani S, et al. Preoperative chemotherapy in children with high-risk medulloblastomas: a feasibility study. J Neurosurg 2005; 103:312-318. (Pubitemid 44954885)
41. Schuler D, Somlo P, Koos R, et al. The treatment of malignant scala posterior tumors in children. II: Preliminary result of the pre and postoperative adjuvant chemotherapy of scala posterior tumors. Med Pediatr Oncol 1993; 21:274-279. (Pubitemid 23117154)
42. Bouffet E, Bernard JL, Frappaz D, et al. M4 protocol for cerebellar medulloblastoma: supratentorial radiotherapy may not be avoided. Int J Radiat Oncol Biol Phys 1992; 24:79-85.
43. Thomas PR, Deutsch M, Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000; 18:3004-3011. (Pubitemid 30644125)
44. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group Study. J Clin Oncol 1999; 17:2127-2136. (Pubitemid 29318845)
45. Oyharcabal-Bourden V, Kalifa C, Gentet JC, et al. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. J Clin Oncol 2005; 23:4726-4734. (Pubitemid 46224076)
46. Mulhern RK, Kepner JL, Thomas PR, et al. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol 1998; 16:1723-1728.
47. Allen JC, Donahue B, DaRosso R, Nirenberg A. Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medulloblastoma and other primitive neuroectodermal tumors. Int J Radiat Oncol Biol Phys 1996; 36:1155-1161. (Pubitemid 27014502)
48. Carrie C, Muracciole X, Gomez F, et al. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol. Int J Radiat Oncol Biol Phys 2005; 63:711-716. (Pubitemid 41400056)
49. Prados MD, Edwards MS, Chang SM, et al. Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a Phase II study. Int J Radiat Oncol Biol Phys 1999; 43:279-285. (Pubitemid 29091465)
50. Merchant TE, Kun LE, Krasin MJ, et al. Multiinstitution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys 2008; 70:782-787. (Pubitemid 351199711)
51. Athar BS, Paganetti H. Comparison of second cancer risk due to out-of-field doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans. Radiother Oncol 2011; 98:87-92.
52. Fossati P, Ricardi U, Orecchia R. Pediatric medulloblastoma: toxicity of current treatment and potential role of proton therapy. Cancer Treat Rev 2009; 35:79-96.
53. Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 2005; 6:573-580. (Pubitemid 41051935)
54. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005; 352:978-986. (Pubitemid 40349500)
55. Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 2005; 23:7621-7631. (Pubitemid 46291826)
56. Von Bueren AO, von Hoff K, Pietsch T, et al. Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro Oncol 2011; 13:669-679.
57. Von Bueren AO, Oehler C, Shalaby T, et al. c-MYC expression sensitizes medulloblastoma cells to radio-and chemotherapy and has no impact on response in medulloblastoma patients. BMC Cancer 2011; 11:74-84.
58. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24:4202-4208. (Pubitemid 46622300)
59. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999; 17:832-845. (Pubitemid 29109313)
60. Pfister S, Remke M, Benner A, et al. Outcome prediction in pediatric medulloblastomabased onDNAcopy-number aberrations of chromosomes 6qand17q and the MYC and MYCN loci. J Clin Oncol 2009; 27:1627-1636.
61. Bailey CC, Gnekow A, Wellek S, et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995; 25:166-178.
62. Gentet JC, Bouffet E, Doz F, et al. Preirradiation chemotherapy including 'eight drugs in 1 day' regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study. J Neurosurg 1995; 82:608-614.
63. Verlooy J, Mosseri V, Bracard S, et al. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. Eur J Cancer 2006; 42:3004-3014. (Pubitemid 44667471)
64. Strother D, Ashley D, Kellie SJ, et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 2001; 19:2696-2704. (Pubitemid 32441375)
65. Gandola L, Massimino M, Cefalo G, et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 2009; 27:566-571.
66. Kortmann RD, Kuhl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 2000; 46:269-279. (Pubitemid 30067775)
67. Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011; 29:1400-1407.
68. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173-1178.
69. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326:572-574.
70. Di Rocco C, Chieffo D, Frassanito P, et al. Heralding cerebellar mutism: evidence for presurgical language impairment as primary risk factor in posterior fossa surgery. Cerebellum 2011. [Epub ahead of print]
71. Mulhern RK, Palmer SL, Reddick WE, et al. Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol 2001; 19:472-479. (Pubitemid 32112861)
72. Frange P, Alapetite C, Gaboriaud G, et al. From childhood to adulthood: longterm outcome of medulloblastoma patients. The Institut Curie experience. J Neurooncol 2009; 95:271-279.
73. Ris MD, Packer R, Goldwein J, et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study (1980-2000). J Clin Oncol 2001; 19:3470-3476. (Pubitemid 32730083)
74. Kieffer-Renaux V, Bulteau C, Grill J, et al. Patterns of neuropsychological deficits in children with medulloblastoma according to craniospatial irradiation doses. Dev Med Child Neurol 2000; 42:741-745.
75. Palmer SL, Hassall T, Evankovich K, et al. Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma. Neuro Oncol 2010; 12:1311-1317.
76. Musial-Bright L, Fengler R, Henze G, Hernaiz Driever P. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. Childs Nerv Syst 2011; 27:407-413.
77. Mulhern RK. Correlation of the Health Utilities Index Mark 2 cognition scale and neuropsychological functioning among survivors of childhood medulloblastoma. Int J Cancer Suppl 1999; 12:91-94.
78. Heikens J, Michiels EM, Behrendt H, et al. Long-term neuro-endocrine sequelae after treatment for childhood medulloblastoma. Eur J Cancer 1998; 34:1592-1597. (Pubitemid 28446343)
79. Slampa P, Pavelka Z, Dusek L, et al. Long term treatment results of childhood medulloblastoma by craniospinal irradiation in supine position. Neoplasma 2007; 54:62-67.
80. Xu W, Janss A, Packer RJ, et al. Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy. Neuro Oncol 2004; 6:113-118. (Pubitemid 38455757)
81. Ciaccio M, Gil S, Guercio G, et al. Effectiveness of rhGH treatment on adult height in GH-deficient childhood survivors of medulloblastoma. Horm Res Paediatr 2010; 73:281-286.
82. Ranke MB, Price DA, Lindberg A, et al. Final height in children with medulloblastoma treated with growth hormone. Horm Res 2005; 64:28-34. (Pubitemid 41207075)
83. Packer RJ, Boyett JM, Janss AJ, et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 2001; 19:480-487. (Pubitemid 32112862)
84. Corrias A, Einaudi S, Ricardi U, et al. Thyroid diseases in patients treated during prepuberty for medulloblastoma with different radiotherapic protocols. J Endocrinol Invest 2001; 24:387-392. (Pubitemid 32573787)
85. Cuny A, Trivin C, Brailly-Tabard S, et al. Inhibin B and antimullerian hormone as markers of gonadal function after treatment for medulloblastoma or posterior fossa ependymoma during childhood. J Pediatr 2011; 158: 1016-1022.